Forma Therapeutics Holdings ($FMTX)

Stock Image

FMTX Overview

Forma Therapeutics Holdings, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers.Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors.The company was founded in 2007 and is headquartered in Watertown, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT Forma Therapeutics Holdings

Stay up to date with the best of Bullish each week.


Stay up to date with the best of Bullish each week.